Funds raised: $12.7 million | Founded 2017
Antoxerene performs pipeline testing for small molecule drugs that target protein-drug and protein-protein interactions. The platform is based on a patent-pending production technology, which enables manufacturing of impossible to express protein targets in biologically active form, at scale.
Funds raised: In progress | Founded 2018
Auctus Biologics is a biotechnology company that is developing an antibody mimetic scaffold for clinical and diagnostic applications that is gut stable and orally bioavailable.
Funds raised: $500k | Founded 2018
Repair Biotechnologies is engaged in developing forms of gene and protein therapy aimed at aspects of aging. Their first area of focus is reversal of age-associated thymic atrophy and consequent loss of immune function. The second is a novel means to reverse atherosclerosis by providing circulating monocytes with the ability to break down cholesterol.
Funds raised: $300k | Founded 2016
RecombiPure is a biotechnology company specializing in next-generation protein expression and purification technologies. Our product offerings include patent-pending chromatography resins, columns and reagents, as well as recombinant proteins and custom protein expression services.
Funds raised: $750k | Founded 2015
Lysoclear is developing an enzyme therapy for the treatment of dry age-related macular degeneration, the leading cause of vision loss in old age.